Avenue Therapeutics, Inc. – NASDAQ:ATXI

Add to watchlist

$0.59

-1.35

-69.59%

Market open

Closed in about 4 hours

-44.25%

month

-44.25%

quarter

+1090.91%

year

Market Cap	3.43M
Enterprise value	N/A

P/E	-0.3
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	0.64
PEG ratio	N/A
EPS	-8.15

Revenue	N/A
EBITDA	-11.76M
Income	-7.18M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Avenue Therapeutics, Inc. (NASDAQ:ATXI): Profit margin
Jun 2023	0	-4.00M
Sep 2023	0	526K
Dec 2023	0	640K
Mar 2024	0	-4.34M

Avenue Therapeutics Financials Estimate

Q Y

Avenue Therapeutics, Inc. (NASDAQ:ATXI): Analyst Estimates
2025	258.96M	-15.2M	-5.87%
2026	0	-17.36M
2027	0	-480.15K
2028	46.50M	196.29K	0.42%

Analysts Price target
Financials & Ratios estimates

Avenue Therapeutics, Inc. (NASDAQ:ATXI): Earnings per share (EPS)
2022-08-15	-0.45	-0.45
2022-11-10	-0.45	-0.45
2023-03-30	1.23	1.23

Avenue Therapeutics, Inc. (NASDAQ:ATXI): Debt to assets
Jun 2023	1666000	7.81M	468.91%
Sep 2023	502000	5.02M	1000.8%
Dec 2023	1850000	1.19M	64.65%
Mar 2024	3310000	1.41M	42.66%

Avenue Therapeutics, Inc. (NASDAQ:ATXI): Cash Flow
Jun 2023	-4.66M	-2M	0
Sep 2023	-889K	-1M	479K
Dec 2023	-2.32M	3M	3.94M
Mar 2024	-3.12M	0	4.53M

Avenue Therapeutics alternative data

Avenue Therapeutics, Inc. (NASDAQ:ATXI): Employee count
Aug 2023	2
Sep 2023	2
Oct 2023	2
Nov 2023	2
Dec 2023	2
Jan 2024	2
Feb 2024	2
Mar 2024	3
Apr 2024	3
May 2024	3
Jun 2024	3
Jul 2024	3

Avenue Therapeutics
Hedge Funds Holdings Q1 2023

6.15% -24.47%

of ATXI is owned by hedge funds

9 -4

hedge funds hold ATXI stock

134.41K -314.4K

shares is hold by hedge funds

ATXI hedge funds holdings changes

Avenue Therapeutics
Insider Trading

Avenue Therapeutics, Inc. (NASDAQ:ATXI): Insider trades (number of shares)
Period	Buy	Sel
Sep 2024	500	0
Nov 2024	0	61
Dec 2024	0	23

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	2 Dec 2024	HERSKOWITZ NEIL director director	COMMON STOCK, PAR VALUE $0.0001	23	$2	$46
Sale	5 Nov 2024	KRANZLER JAY D director director	COMMON STOCK, PAR VALUE $0.0001	61	$2.24	$137
Purchase	30 Sep 2024	KRANZLER JAY D director director	COMMON STOCK, PAR VALUE $0.0001	497	$2.5	$1,243
Purchase	27 Sep 2024	KRANZLER JAY D director director	COMMON STOCK, PAR VALUE $0.0001	3	$2.4	$7
Sale	11 Dec 2023	DAVIDOW ROBERT L 10 percent owner 10 percent owner	Common Stock	264,000	$0.14	$36,960
Sale	11 Dec 2023	DAVIDOW ROBERT L 10 percent owner 10 percent owner	Common Stock	126,000	$0.14	$17,640
Sale	11 Dec 2023	DAVIDOW ROBERT L 10 percent owner 10 percent owner	Common Stock	128,000	$0.14	$17,920
Sale	11 Dec 2023	DAVIDOW ROBERT L 10 percent owner 10 percent owner	Common Stock	18,000	$0.15	$2,700
Sale	11 Dec 2023	DAVIDOW ROBERT L 10 percent owner 10 percent owner	Common Stock	20,000	$0.14	$2,800
Sale	11 Dec 2023	DAVIDOW ROBERT L 10 percent owner 10 percent owner	Common Stock	61,000	$0.14	$8,540

ATXI insider trading transactions

Avenue Therapeutics
Executives

Insider	Age	Since	Compensation
Dr. Xiaoqin Lu M.D. (1975) Pres, Chief Executive Officer & Director	50		$443,030
Mr. Joseph Walter Vazzano (1984) Chief Financial Officer, Principal Financial Officer & Company Sec.	41		$214,890

Avenue Therapeutics
Latest News

Thursday, 14 November 2024
16:05	Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights	globenewswire.com
Wednesday, 9 October 2024
08:30	Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit	globenewswire.com
Tuesday, 3 September 2024
08:30	Avenue Therapeutics to Participate in Upcoming Investor Conferences	globenewswire.com
Friday, 9 August 2024
16:05	Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights	globenewswire.com
Thursday, 20 June 2024
08:30	Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference	globenewswire.com
Thursday, 16 May 2024
08:30	Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)	globenewswire.com
Wednesday, 15 May 2024
08:30	Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights	globenewswire.com
Monday, 29 April 2024
08:00	Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds	globenewswire.com
Wednesday, 24 April 2024
07:30	Avenue Therapeutics Announces Reverse Stock Split	globenewswire.com
Monday, 25 March 2024
08:30	Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024	globenewswire.com
Monday, 18 March 2024
16:05	Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights	globenewswire.com
Friday, 15 March 2024
08:15	Avenue Therapeutics Receives Positive Listing Determination from Nasdaq	globenewswire.com
Monday, 11 March 2024
08:00	Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting	GlobeNewsWire
Friday, 1 December 2023
08:30	Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting	GlobeNewsWire
Wednesday, 29 November 2023
08:05	Why Is Avenue Therapeutics (ATXI) Stock Up 59% Today?	InvestorPlace
Tuesday, 5 September 2023
08:30	Avenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference	GlobeNewsWire
Thursday, 27 April 2023
08:30	Avenue Therapeutics to Present at Aegis Capital Virtual Conference	GlobeNewsWire
Monday, 17 October 2022
19:41	These Were The Five Best And Worst Performing Healthcare Stocks In September 2022	24/7 Wall Street
Sunday, 16 October 2022
11:30	New to Trading Penny Stocks? Must Knows in 2022	PennyStocks
Friday, 7 October 2022
09:21	What In The World Is Going On With Avenue Therapeutics Stock?	Benzinga
Tuesday, 27 September 2022
13:40	ATXI Stock Alert: What to Know as Avenue Therapeutics Soars 150%	InvestorPlace
Friday, 23 September 2022
10:49	What Is Going on With Avenue Therapeutics (ATXI) Stock Today?	InvestorPlace
08:44	Avenue Therapeutics (ATXI) Stock: 1-For-15 Reverse Split Goes Into Effect	Pulse2
06:00	Reddit Penny Stocks to Watch as September Ends	PennyStocks
Thursday, 8 September 2022
10:40	Hot Penny Stocks To Buy For Under $0.99 This Week	PennyStocks
Friday, 11 March 2022
14:31	Top Biotech Penny Stocks to Buy Now? 3 to Watch in March	PennyStocks
Wednesday, 2 March 2022
09:29	Trading Penny Stocks? Top Stock Market News for March 2nd, 2022	PennyStocks
Tuesday, 30 November 2021
06:07	Avenue Therapeutics (ATXI) Stock: Why The Price Surged	Pulse2

Frequently Asked Questions (FAQ)

What's the price of Avenue Therapeutics stock today?

One share of Avenue Therapeutics stock can currently be purchased for approximately $0.59.
When is Avenue Therapeutics's next earnings date?

Unfortunately, Avenue Therapeutics's (ATXI) next earnings date is currently unknown.
Does Avenue Therapeutics pay dividends?

No, Avenue Therapeutics does not pay dividends.
How much money does Avenue Therapeutics make?

Avenue Therapeutics has a market capitalization of 3.43M. Avenue Therapeutics made a loss 10.38M US dollars in net income (profit) last year or $1.23 on an earnings per share basis.
What is Avenue Therapeutics's stock symbol?

Avenue Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "ATXI".
What is Avenue Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Avenue Therapeutics?

Shares of Avenue Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Avenue Therapeutics's key executives?
Avenue Therapeutics's management team includes the following people:
- Dr. Xiaoqin Lu M.D. Pres, Chief Executive Officer & Director(age: 50, pay: $443,030)
- Mr. Joseph Walter Vazzano Chief Financial Officer, Principal Financial Officer & Company Sec.(age: 41, pay: $214,890)
How many employees does Avenue Therapeutics have?

As Jul 2024, Avenue Therapeutics employs 3 workers.
When Avenue Therapeutics went public?

Avenue Therapeutics, Inc. is publicly traded company for more then 8 years since IPO on 27 Jun 2017.
What is Avenue Therapeutics's official website?

The official website for Avenue Therapeutics is avenuetx.com.
Where are Avenue Therapeutics's headquarters?

Avenue Therapeutics is headquartered at 1140 Avenue of the America, New York, NY.
How can i contact Avenue Therapeutics?

Avenue Therapeutics's mailing address is 1140 Avenue of the America, New York, NY and company can be reached via phone at +7 816524500.

Avenue Therapeutics, Inc.

avenuetx.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.

+7 816524500

1140 Avenue of the America
New York, NY 10036

CIK: 0001644963
ISIN: US05360L3042
CUSIP: 05360L205